Odan-Indomethacin · DIN 02231799 · 50 mg · suppository
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Odan-Indomethacin · DIN 02231799
Manufacturer: Odan Laboratories Ltd.; listing date 1999-04-15
Health Canada: Marketed since 2026-06-18 · brand ODAN-INDOMETHACIN · ATC M01AB01 INDOMETACIN · form Suppository · route Rectal · ingredients INDOMETHACIN 50 MG/SUP · company Odan laboratoriesltd · schedule Prescription
Odan-Indomethacin: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2500). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231799)
Source record
DIN 02231799: Odan-Indomethacin
Raw flags: sec3=Y
Item: 280804025; group id 383; item number 0917; lccId None; manufacturer id ODN
Source form: Sup; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2500; ministry $1.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231799
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51232
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Indocid · DIN 00594466 · not recorded
Shortage status: not checked (no credentials)